Related Experiment Video

Updated: May 25, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype

Christine Didier1, Cécile Demur, Fanny Grimal

  • 1INSERM, U1037, Cancer Research Center of Toulouse, CNRS ERL 5294, Toulouse, France. christine.didier@inserm.fr

Cancer Biology & Therapy
|January 20, 2012
PubMed

Insights

Checkpoint abrogation using AZD7762, a CHK1/2 kinase inhibitor, enhances chemotherapy efficacy in acute myeloid leukemia (AML) by targeting leukemic progenitors. This approach shows promise for treating chemoresistant AML, especially in patients with genomic instability.

Area of Science:

  • Oncology
  • Cell Biology
  • Genetics

Background:

  • Cell cycle checkpoints are crucial targets for novel anticancer therapies.
  • Acute myeloid leukemia (AML) often exhibits genomic instability and chemoresistance, necessitating improved treatment strategies.

Purpose of the Study:

  • To investigate the efficacy of checkpoint abrogation using AZD7762, a CHK1/2 kinase inhibitor, in combination with genotoxic treatment for AML.
  • To identify potential biomarkers for selecting AML patients who may benefit from this combined therapy.
  • To determine if AZD7762 targets primitive leukemic progenitor cells responsible for AML relapse.

Main Methods:

  • Treatment of immature KG1a leukemic cell line and primary AML patient samples with AZD7762 and genotoxic agents.
  • Analysis of treatment efficacy in relation to karyotype and constitutive DNA-damage levels.
  • Flow cytometry to assess the impact of AZD7762 on CD34(+)CD38(-)CD123(+) leukemic progenitors.
  • Evaluation of AZD7762's effect on normal hematopoietic progenitor clonogenic potential.

Main Results:

  • Checkpoint abrogation by AZD7762 significantly enhanced genotoxic treatment efficacy in AML cells and patient samples, particularly those with complex karyotypes.
  • Elevated constitutive DNA-damage levels may predict patient response to combined checkpoint inhibitor and chemotherapy.
  • AZD7762 was shown to target CD34(+)CD38(-)CD123(+) primitive leukemic progenitors, implicated in AML relapse.
  • Normal hematopoietic progenitors' clonogenic potential was not adversely affected by CHK1 inhibition.

Conclusions:

  • AZD7762-mediated checkpoint abrogation is a promising strategy to enhance chemotherapy efficacy in AML, especially in chemoresistant cases.
  • Constitutive DNA-damage levels could serve as predictive biomarkers for patient selection in AML treatment.
  • Targeting primitive leukemic progenitors with AZD7762 offers a novel approach to combat AML relapse.
  • CHK1 inhibition demonstrates a favorable safety profile regarding normal hematopoietic stem cells.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...